Superluminal Medicines

About:

Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.

Website: https://www.superluminalrx.com

Top Investors: NVIDIA, Eli Lilly, Insight Partners, Gaingels, Cooley

Description:

Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform quickly creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. They leverage cutting-edge computational and machine-learning techniques to accelerate identifying and optimizing novel drug candidates. Their approach combines high-throughput experimental data with advanced algorithms to uncover therapeutic compounds faster and more efficiently than traditional methods.

Total Funding Amount:

$153M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2022-01-01

Founders:

Ajay Yekkirala, Cony D'Cruz

Number of Employees:

1-10

Last Funding Date:

2024-09-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai